Delving into the Latest Updates on Gabapentin/B-complex with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Gabapentin+vitamin B, Gavindo

Target

CACNA2D1 x CACNA2D2 x MUT

Action

blockers, stimulants

Mechanism

CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers), MUT stimulants(Methylmalonyl-CoA Mutase stimulants)

+ [1]

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Merck KGaA

Active Organization-

Inactive Organization

Merck KGaA

License Organization-

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

This is a prospective, randomized, double blind, comparative, experimental controlled Phase 3 clinical trial to assess the efficacy, safety and superiority of F0343 (gabapentin combined with B vitamins) compared to gabapentin alone for treating neuropathic pain in subjects with chronic distal diabetic polyneuropathy.

Start Date01 Feb 2008

Sponsor / Collaborator

Merck KGaA

[+1]

100 Clinical Results associated with Gabapentin/B-complex

Login to view more data

100 Translational Medicine associated with Gabapentin/B-complex

Login to view more data

100 Patents (Medical) associated with Gabapentin/B-complex

Login to view more data

1

Literatures (Medical) associated with Gabapentin/B-complex

01 Mar 2012·World Journal of Microbiology and BiotechnologyQ4 · ENGINEERING & TECHNOLOGY

Genome shuffling improves thermotolerance and glutamic acid production of Corynebacteria glutamicum

Q4 · ENGINEERING & TECHNOLOGY

Article

Author: Zhi-Hao Sun ; Ye Ni ; Qiao-Yan Du ; Miao Liu ; Pu Zheng ; Xiao-de Liu

Genome shuffling was used to improve the thermotolerance of L: -glutamic acid-producing strain Corynebacteria glutamicum. Five strains with subtle improvements in high temperature tolerance and productivity were selected by ultraviolet irradiation and diethyl sulfate mutagenesis. An improved strain (F343) was obtained by three rounds of genome shuffling of the five strains as mentioned above. The cell density of F343 was four times higher than that of ancestor strains after 24 h of cultivation at 44°C, and importantly, the yield of L: -glutamic acid was increased by 1.8-times comparing with that of the ancestor strain at 38°C in a 5-L fermentor. With glucose supplement and two-stage pH control, the L: -glutamate acid concentration of F343 reached 119 g/L after fermentation for 30 h. The genetic diversity between F343 and its ancestors was also evaluated by amplified fragment length polymorphism analysis. Results suggest that the phenotypes for both thermotolerance and L: -glutamic acid production in F343 were evolved.

100 Deals associated with Gabapentin/B-complex

Login to view more data

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01364298 (CTgov)	Phase 4	Diabetic peripheral neuropathic pain	353	Gabapentin/B-complex (Gabapentin/B-complex)	cjrkwjbrxi(gqrftxdlel) = mbnxxdebwy zwgidoyyrw (xszwucycbo, ycotdvngwd - kqykfiviha) View more	-	06 Feb 2014
				Pregabalin (Pregabalin)	cjrkwjbrxi(gqrftxdlel) = mvdlyoggub zwgidoyyrw (xszwucycbo, nrlvmwpnzk - vhptgdwbzo) View more
NCT01364298 (EASD2012)	Phase 4	Diabetic peripheral neuropathy	323	Gabapentin/vitamins B1/B12 fixed combination (GVB)	(pgektzchgi) = For GVB group, 65/146 patients (44.52%) presented at least one adverse event. For pregaba group, figures were 76/145 and 52.41%, respectively. xxqfbudufo (ojfghztanp ) View more	Positive	04 Oct 2012
				Pregabalin (pregaba)